UNASSIGNED: 174 Background: No prospective, randomized comparative efficacy trial exists to guide treatment of definitively managed @entity263 @entity1 . Despite this, treatment selection varies nationally and we attempt to assess these patterns of use. METHODS: The SEER database was queried to identify cases of @entity263 diagnosed between 1998-2008. The modalities identified were brachytherapy (brachy), combination of brachytherapy and external beam radiation (CombRT), external beam radiotherapy (EBRT), radical prostatectomy and external beam radiotherapy (RP+RT), and radical prostatectomy (RP). The number of cases by year, @entity1 age and SEER region was computed. RESULTS: There were 361,135 @entity1 in this analysis: 12.4% brachy, 6.8% CombRT, 27.5% EBRT, 3.1% RP+RT, and 50.3% RP. As expected, treatment modality varied by age with younger @entity1 more likely to receive RP and older @entity1 more likely to receive EBRT or brachy. There was some variation in choice of treatment modality over time: 6.6% for brachy; 4.2% for CombRT; 1.9% for EBRT; 2.0% for RP+RT; and 7.8% for RP. The variation in treatment modality by region was surprisingly wide (table): 14.4% for brachy; 25.5% for CombRT; 28.5% for EBRT; 3.8% for RP+RT; and 26.8% for RP. CONCLUSIONS: Choice of @entity263 treatment modality varies by age, year of treatment, and most notably geographical region. Surprisingly the changes in reimbursement rates over the study period seem to have had minimal impact on choice of treatment modality. The regional variation implies that affiliations among healthcare providers significantly impact treatment. [Table: see text].

Variations in treatment modality use for the definitive management of XXXX in the United States.

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'man', 'men'] @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']
@entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']
